Recruiting
Phase 1

A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies

Sponsor:

Regeneron Pharmaceuticals

Code:

NCT02651662

Conditions

Relapsed/Refractory Aggressive B-Cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

cemiplimab

odronextamab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information